These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24958324)

  • 1. Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.
    Tryfonidis K; Kafousi M; Perraki M; Apostolaki S; Agelaki S; Georgoulias V; Stathopoulos E; Mavroudis D
    Clin Breast Cancer; 2014 Dec; 14(6):442-50. PubMed ID: 24958324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
    Ignatiadis M; Perraki M; Apostolaki S; Politaki E; Xenidis N; Kafousi M; Stathopoulos E; Lianidou E; Sotiriou C; Georgoulias V; Mavroudis D
    Clin Breast Cancer; 2007 Dec; 7(11):883-9. PubMed ID: 18269779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
    Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
    J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features.
    Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M
    Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
    Xenidis N; Perraki M; Apostolaki S; Agelaki S; Kalbakis K; Vardakis N; Kalykaki A; Xyrafas A; Kakolyris S; Mavroudis D; Georgoulias V
    Br J Cancer; 2013 Feb; 108(3):549-56. PubMed ID: 23329233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
    Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
    Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.
    Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D
    Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
    Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
    Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
    Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
    Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
    Xenidis N; Vlachonikolis I; Mavroudis D; Perraki M; Stathopoulou A; Malamos N; Kouroussis C; Kakolyris S; Apostolaki S; Vardakis N; Lianidou E; Georgoulias V
    Ann Oncol; 2003 Jun; 14(6):849-55. PubMed ID: 12796021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
    Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
    J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.
    Apostolaki S; Perraki M; Kallergi G; Kafousi M; Papadopoulos S; Kotsakis A; Pallis A; Xenidis N; Kalmanti L; Kalbakis K; Agelaki S; Kalykaki A; Stournaras C; Stathopoulos E; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2009 Oct; 117(3):525-34. PubMed ID: 19016323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
    Georgoulias V; Apostolaki S; Bozionelou V; Politaki E; Perraki M; Georgoulia N; Kalbakis K; Kotsakis A; Xyrafas A; Agelaki S; Mavroudis D
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1217-25. PubMed ID: 25344760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.
    Daskalakis M; Mavroudis D; Sanidas E; Apostolaki S; Askoxylakis I; de Bree E; Georgoulias V; Melissas J
    Eur J Surg Oncol; 2011 May; 37(5):404-10. PubMed ID: 21376504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.
    Ignatiadis M; Kallergi G; Ntoulia M; Perraki M; Apostolaki S; Kafousi M; Chlouverakis G; Stathopoulos E; Lianidou E; Georgoulias V; Mavroudis D
    Clin Cancer Res; 2008 May; 14(9):2593-600. PubMed ID: 18451221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
    Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
    Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.